Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_1
2
40%
Ph phase_2
1
20%
Ph phase_3
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)

Trials by Status

completed240%
not_yet_recruiting120%
unknown240%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_2

Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

NCT06919523
completedphase_1

Dapagliflozin Effects on Hypoglycemia

NCT03704818
unknownphase_3

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

NCT04333823
unknownearly_phase_1

Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

NCT04806633
completedphase_1

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

NCT02582840

Clinical Trials (5)

Showing 5 of 5 trials
NCT06919523Phase 2

Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

Not Yet Recruiting
NCT03704818Phase 1

Dapagliflozin Effects on Hypoglycemia

Completed
NCT04333823Phase 3

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

Unknown
NCT04806633Early Phase 1

Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

Unknown
NCT02582840Phase 1

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5